Qun (Kevin) Yin

Qun (Kevin) Yin has a strong background in the biopharmaceutical industry, with extensive experience in formulation development, technology enablement, and discovery and development of various drugs. Qun (Kevin) started their career in 1995 as a Scientist at AFFYMAX Research Institute/ Glaxosmithkline, PLC, and later moved on to Affymax Inc. as a Scientist II. During their time at Affymax, they were involved in the discovery and development of the EPO stimulating drug OMONTYS. In 2006, they joined KAI Pharmaceuticals/ Amgen as a Senior Research Scientist, where they contributed to the discovery and development of ParsabivTM for the treatment of Secondary Hyperparathyroidism. Qun then worked at Sutro Biopharma, Inc. as a Senior Scientist, where they focused on designing and synthesizing novel amino acids, cytotoxins, and linkers for the construction of antibody drug conjugates to treat cancer. Currently, they are working at Applied Molecular Transport as a Senior Principal Scientist, primarily involved in the formulation development of anti-inflammatory biologics in clinical trials and the technology enablement of oral biopharmaceuticals and RNA therapeutics for gastrointestinal targeting or systemic delivery.

Qun (Kevin) Yin's education history includes their attendance at Auburn University. However, no information regarding the start and end years, degree name, or field of study is available.